CRISPR/Cas9-compatible plasmids enabling seven dominant genetic selection methods for the human fungal pathogen

Michael J Boucher1, Hiten D Madhani1

  • 1Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.

Microbiology Spectrum
|September 25, 2025
PubMed

Insights

New genetic markers blasticidin S resistance (BSD/BSR) and phleomycin resistance (BLE) expand Cryptococcus neoformans research tools. This increases the total dominant genetic selection methods to seven, aiding fungal meningitis pathogen studies.

Area of Science:

  • Mycology
  • Molecular Biology
  • Genetics

Background:

  • Cryptococcus neoformans is a major cause of fungal meningitis and a model for eukaryotic biology.
  • Current genetic manipulation relies on limited dominant markers (NAT, NEO, HYG, amdS).
  • Need for additional selection methods to facilitate multiple genetic modifications in C. neoformans strains.

Purpose of the Study:

  • To identify and validate novel dominant genetic selection methods for C. neoformans.
  • To expand the toolkit for combinatorial genetic manipulation in C. neoformans.
  • To facilitate CRISPR/Cas9-mediated genome modification with new markers.

Main Methods:

  • Identification of blasticidin S resistance (BSD/BSR) as a novel dominant marker.
  • Validation of phleomycin resistance (BLE) as a dominant marker.
  • Incorporation of BSD, BSR, BLE, and ptxD markers into a vector series for PCR-based construction of fused marker-sgRNA products.

Main Results:

  • Blasticidin S resistance (BSD/BSR) is established as a novel dominant selection method.
  • Phleomycin resistance (BLE) is validated as an additional dominant selection method.
  • The study expands the available dominant genetic selection methods for C. neoformans to seven (five drug, two prototrophic).

Conclusions:

  • The expanded set of dominant selection markers enhances the utility of C. neoformans as a model organism.
  • These new tools provide flexibility for sequential genetic modifications in C. neoformans.
  • The developed vector series supports efficient CRISPR/Cas9-mediated genome editing.